ABBV vs MRNA
By Alex · Tickerpine
AbbVie Inc. vs Moderna, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | MRNA |
|---|---|---|
| Price | $253.35 | $67.27 |
| Market cap | $447.62B | $26.69B |
| P/E ratio | 123.6 | — |
| ROE | — | -36.56% |
| Profit margin | 5.79% | -143.55% |
| Revenue growth | 12.40% | 260.20% |
| Dividend yield | 2.73% | — |
| Beta | 0.31 | 1.03 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs MRNA in plain English
- ABBV is the bigger company — about 16.8× the market cap of MRNA.
- MRNA is growing revenue faster (260% vs 12%).
- ABBV pays a dividend (2.73%) while the other effectively doesn't.
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
MRNA return calculator
See what $1,000 in Moderna, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.